Illumina , manufacturer of gene - sequencing products , saw a 32 % increase in profit in its fourth quarter , as the company 's expenses rose from $ 122.2 m to $ 147.3 m . However it exceeded even its own expectations for earnings , all be they lower than a year earlier , including items at $ 104 m or 70 cents per share ( compared with $ 104 m or $ 1.03 per share ) . Earlier this month , Illumina launched Grail , a liquid biopsy company that will develop a test to detect evidence of cancer in the blood . The company expects revenues to exceed 16 % in the next fiscal year , with adjusted earnings on a per - share basis between $ 3.55 and $ 3.65 .
Illumina, maker of gene-sequencing machines, saw a 32% decline in profit in its fourth quarter, as the company's expenses rose from $122.2m to $147.3m. However it exceeded even its own expectations for earnings, all be they lower than a year earlier, including items at $104m or 70 cents per share (compared with $153m or $1.03 per share). Earlier this month, Illumina launched Grail, a liquid biopsy company that will develop a test to detect evidence of cancer in the blood. The company expects revenues to rise 16% in the next fiscal year, with adjusted earnings on a per-share basis between $3.55 and $3.65.